Meta-analysis of dropout rates in randomized controlled clinical trials

Der Schmerz - Tập 25 - Trang 296-305 - 2011
M. Gehling1, B. Hermann2, M. Tryba1
1Dept. of Anesthesiology, Intensive Care Medicine and Pain Therapy, Klinikum Kassel GmbH, Kassel, Deutschland
2Orthopädische Fachpraxen, Hamburg, Deutschland

Tóm tắt

The interpretation of opioid studies in patients with chronic pain due to osteoarthritis is limited by a high dropout rate. Therefore, the implication of dropouts on the recommendation of opioids in chronic osteoarthritis pain was analyzed. The databases of Medline, Embase, the Cochrane Library, and the Internet from 1990–2009 were searched. Two independent authors included randomized controlled clinical trials investigating the effects of chronic opioid treatment for the management of osteoarthritis pain. In order to calculate the odds ratio, only placebo-controlled trials were included. The primary outcome parameter was the dropout rate. Secondarily, the effect size was calculated. Data extraction was conducted by two independent authors. A total of 19 studies reporting results of 3,871 treatment and 2,080 placebo outcomes were retrieved. Compared to placebo, opioid treatment was associated with a significantly increased total dropout rate (OR=1.3, 95%CI 1.2–1.4). Discontinuation of treatment was related to adverse events (OR=4.0, 95%CI 3.4–4.6). Lack of analgesia was associated with a significantly reduced dropout rate in opioid groups (OR=0.4, 95%CI 0.3–0.5). Analgesic effects were significantly better in opioid-treated patients (p=0.01). In spite of analgesic effects, many osteoarthritis patients prefer to stop chronic opioid use, because of adverse events. Therefore, opioids are not generally recommended in osteoarthritis.

Tài liệu tham khảo

Avouac J, Gossec L, Dougados M (2007) Efficacy and safety of opioids for osteoarthritis: a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage 15:957–965 Babul N, Noveck R, Chipman H et al (2004) Efficacy and safety of extended-release, once-daily tramadol in chronic pain: a randomized 12-week clinical trial in osteoarthritis of the knee. J Pain Symptom Manage 28:59–71 Biegert C, Wagner I, Ludtke R et al (2004) Efficacy and safety of willow bark extract in the treatment of osteoarthritis and rheumatoid arthritis: results of 2 randomized double-blind controlled trials. J Rheumatol 31:2121–2130 Bocanegra TS, Weaver AL, Tindall EA et al (1998) Diclofenac/misoprostol compared with diclofenac in the treatment of osteoarthritis of the knee or hip: a randomized, placebo controlled trial. Arthrotec Osteoarthritis Study Group. J Rheumatol 25:1602–1611 Burch F, Fishman R, Messina N et al (2007) A comparison of the analgesic efficacy of Tramadol Contramid OAD versus placebo in patients with pain due to osteoarthritis. J Pain Symptom Manage 34:328–338 Caldwell JR, Hale ME, Boyd RE et al (1999) Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: a double blind, randomized, multicenter, placebo controlled trial. J Rheumatol 26:862–869 Caldwell JR, Rapoport RJ, Davis JC et al (2002) Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: results from a randomized, placebo-controlled, double-blind trial and an open-label extension trial. J Pain Symptom Manage 23:278–291 Chindalore VL, Craven RA, Yu KP et al (2005) Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex. J Pain 6:392–399 Emkey R, Rosenthal N, Wu SC et al (2004) Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double-blind, placebo-controlled trial. J Rheumatol 31:150–156 Fishman RL, Kistler CJ, Ellerbusch MT et al (2007) Efficacy and safety of 12 weeks of osteoarthritic pain therapy with once-daily tramadol (Tramadol Contramid OAD). J Opioid Manag 3:273–280 Fleischmann RM, Caldwell JR, Roth SM et al (2001) Tramadol for the treatment of joint pain associated with osteoarthritis: a randomized, double-blind, placebo-controlled trial. Curr Ther Res 62:113–128 Gana TJ, Pascual ML, Fleming RR et al (2006) Extended-release tramadol in the treatment of osteoarthritis: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Curr Med Res Opin 22:1391–1401 Gimbel JS, Richards P, Portenoy RK (2003) Controlled-release oxycodone for pain in diabetic neuropathy. Neurology 60:927–934 Harati Y, Gooch C, Swenson M et al (1998) Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 50:1842–1846 Hartrick C, Van Hove I, Stegmann JU et al (2009) Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study. Clin Ther 31:260–271 Jadad AR, Mcquay HJ (1996) Meta-analyses to evaluate analgesic interventions: a systematic qualitative review of their methodology. J Clin Epidemiol 49:235–243 Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12 Kivitz A, Ma C, Ahdieh H et al (2006) A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee. Clin Ther 28:352–364 Kosinski M, Janagap C, Gajria K et al (2007) Pain relief and pain-related sleep disturbance with extended-release tramadol in patients with osteoarthritis. Curr Med Res Opin 23:1615–1626 Langford R, Mckenna F, Ratcliffe S et al (2006) Transdermal fentanyl for improvement of pain and functioning in osteoarthritis: a randomized, placebo-controlled trial. Arthritis Rheum 54:1829–1837 Lonts (2009) S3-Guideline LONTS. http://www.uni-duesseldorf.de/AWMF/II/041–003m.htm Malonne H, Coffiner M, Sonet B et al (2004) Efficacy and tolerability of sustained-release tramadol in the treatment of symptomatic osteoarthritis of the hip or knee: a multicenter, randomized, double-blind, placebo-controlled study. Clin Ther 26:1774–1782 Markenson JA, Croft J, Zhang PG et al (2005) Treatment of persistent pain associated with osteoarthritis with controlled-release oxycodone tablets in a randomized controlled clinical trial. Clin J Pain 21:524–535 Matsumoto AK, Babul N, Ahdieh H (2005) Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled phase III trial. Pain Med 6:357–366 Moore A, Mcquay H (2005) Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids. Arthritis Res Ther 7:R1046–1051 Nuesch E, Rutjes AW, Husni E et al (2010) Oral or transdermal opioids for osteoarthritis of the hip or knee. Cochrane Database Syst Rev Peloso PM, Bellamy N, Bensen W et al (2000) Double blind randomized placebo control trial of controlled release codeine in the treatment of osteoarthritis of the hip or knee. J Rheumatol 27:764–771 Reinecke H, Sorgatz H (2009) S3 guideline LONTS. Long-term administration of opioids for non-tumor pain. Schmerz 23:440–447 Roth SH, Fleischmann RM, Burch FX et al (2000) Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation. Arch Intern Med 160:853–860 Schmidt H, Lowenstein O, Hesselbarth S et al (2010) S3 guidelines LONTS (Long-term administration of opioids for non-tumor pain). Schmerz 24:71–72; author reply 72 Schnitzer TJ, Kamin M, Olson WH (1999) Tramadol allows reduction of naproxen dose among patients with naproxen-responsive osteoarthritis pain: a randomized, double-blind, placebo-controlled study. Arthritis Rheum 42:1370–1377 Silverfield JC, Kamin M, Wu SC et al (2002) Tramadol/acetaminophen combination tablets for the treatment of osteoarthritis flare pain: a multicenter, outpatient, randomized, double-blind, placebo-controlled, parallel-group, add-on study. Clin Ther 24:282–297 Sindrup SH, Andersen G, Madsen C et al (1999) Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial. Pain 83:85–90 Thorne C, Beaulieu AD, Callaghan DJ et al (2008) A randomized, double-blind, crossover comparison of the efficacy and safety of oral controlled-release tramadol and placebo in patients with painful osteoarthritis. Pain Res Manag 13:93–102 Tolle TR, Treede RD, Zenz M (2009) To give or not to give, that is not the question here! Long-term administration of opioids for non-tumor pain (LONTS). Schmerz 23:437–439 Vorsanger G, Xiang J, Jordan D et al (2007) Post hoc analysis of a randomized, double-blind, placebo-controlled efficacy and tolerability study of tramadol extended release for the treatment of osteoarthritis pain in geriatric patients. Clin Ther 29(Suppl):2520–2535 Watson CP, Babul N (1998) Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 50:1837–1841 Watson CP, Moulin D, Watt-Watson J et al (2003) Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 105:71–78 Yocum D, Fleischmann R, Dalgin P et al (2000) Safety and efficacy of Meloxicam in the treatment of osteoarthritis. Arch Intern Med 160:2947–2954 Zautra AJ, Smith BW (2005) Impact of controlled-release oxycodone on efficacy beliefs and coping efforts among osteoarthritis patients with moderate to severe pain. Clin J Pain 21:471–477